



1653
Attorney Docket No. 71699/57109

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: S. Denmeade, et al. Examiner: S. Liu
Application No.: 09/627,600 Group: 1653
Filed: July 28, 2000
For: ACTIVATION OF PEPTIDE PRODRUGS BY (HK2)

RECEIVED
JUL 15 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 9, 2003

By: 
Sharon Bizokas

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:


Transmitted herewith for filing in the above-referenced patent application are the following documents:

1. Supplemental Information Disclosure Statement (4 pages);
2. Form PTO-1449 (1 page);
3. Copy of Partial European Search Report from the corresponding European Patent Application;
4. Full copies of References for IDS (BA - BH);
5. This transmittal letter (1 page) (x2); and
6. Return Receipt Postcard

The Commissioner is hereby authorized to charge any excess fees that may be required, or credit any overpayment to Deposit Account No. 04-1105. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: July 9, 2003


Jennifer K. Rosenfield, Reg No. 53,531
Intellectual Property Practice Group of
Edwards & Angell, LLP
P.O. Box 9169
Boston, MA 02209
Tel: (617) 439-4444



Attorney Docket No. 71699/57109

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: S. Denmeade, et al. Examiner: S. Liu
Application No.: 09/627,600 Group: 1653
Filed: July 28, 2000
For: ACTIVATION OF PEPTIDE PRODRUGS BY (HK2)

RECEIVED
JUL 15 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box, Alexandria, VA 22313-1450 on July 9, 2003.

By: Sharon Bizokas
Sharon Bizokas

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on Form PTO-1449, attached hereto.

II. COPIES

- a. x Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- b. This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application Serial No. , filed on . The following references were submitted to, and/or cited by, the Office in the prior application (s) and, therefore, are not required to be provided in this application.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

- a. x Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).
- b. A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
See English language Abstracts and drawings
- c. The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)
(check one box)

- a. within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1). No fee or certification is required.
- b. within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2). No fee or certification is required.

In re application of: S. Denmeade, et al.
U.S.S.N.: 09/627,600
Filed: July 28, 2000

- c. x Before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$240.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

- a. No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. . § 1.17(p).
or
b. See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

- a. x each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
b. no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

In re application of: S. Denmeade, et al.
U.S.S.N.: 09/627,600
Filed: July 28, 2000

c. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

 Please charge Deposit Account No. 04-1105 in the amount of \$180.00 for the above-indicated fee. A triplicate copy of this paper is attached.

 x No fee is required.


 The fee in the amount of \$180.00 is enclosed herewith.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule, with a petition if necessary, and charge the appropriate fee to Deposit Account No. **04-1105**.

Respectfully submitted,

Date: July 9, 2003

By:


Jennifer K. Rosenfield, Reg. No. 53,531
Intellectual Property Practice Group of
Edwards & Angell, LLP
P.O. Box 9169
Boston, MA 02209
Tele: (617)-439-4444

Customer No. 21874

FORM PTO-1449

ATTY DOCKET NO.

SERIAL NO.

71699/57109

09/627,600

INFORMATION DISCLOSURE STATEMENT

APPLICANT(S): Denmeade, et al.

FILING DATE:
07/28/00ART UNIT:
1653

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPR

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN YES/NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

BA	Dube, "LA KALLICREINE HK2 PEUT-ELLE FAVORISER LA PROGRESSION DES TUMEURS CANCEREUSES DE LA PROSTATE", Science and Medicine, 14(1):111-113 (1998)
BB	Bougeois et al., Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikrein hkl and hk2", Journal of Biological Chemistry, 272(47):29590-29595 (1997)
BC	Lovgren et al., "Enzymatic action of human glandular kallikrein 2 (hk2): Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors", European Journal of Biochemistry, 262(3):781-789 (1999)
BD	Mikolajczyk et al., "Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors", Prostate, 34(1):44-50 (1998)
BE	Denmeade et al., "ENZYMATIC ACTIVATION OF PRODRUGS BY PROSTATE-SPECIFIC ANTIGEN: TARGETED THERAPY FOR METASTATIC PROSTATE CANCER", Cancer Journal from Scientific American, 4, Suppl. 1:S15-S21 (1998)
BF	Denmeade et al., "Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen", Cancer Research, 58:2537-2540 (1994)
BG	James et al., "BASIC AMINO ACIDS PREDOMINATE IN THE SEQUENTIAL AUTOANTIGENIC DETERMINANTS OF THE SMALL NUCLEAR 70K RIBONUCLEOPROTEIN", Scandinavian Journal of Immunology, 39(6):557-566 (1994)
BH	Pimenta et al., "Specificity of human tissue kallikrein towards substrates containing Phe-Phe pair of amino acids", Biochemical Journal, 339(2):473-479 (1999)

Examiner:

Date: